Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2003

View Archived Issues

NeuGene antisense drugs make progress in infectious disease program

Genzyme and MacroGenics collaborate on therapies for immune-mediated disease

Tripep identifies new candidate drug for HIV

Good gastrointestinal safety profile reported for licofelone in osteoarthritis patients

MMF as effective as i.v. cyclophosphamide in severe lupus nephritis

Doxycycline associated with benefits in osteoarthritis of the knee, rheumatoid arthritis

Absence of causal relationship reported for lymphoma and anti-TNF-alpha drugs

Potential therapeutic effects of atorvastatin in rheumatoid arthritis

Improved organ function and reduced mortality described for drotrecogin alfa (activated) in sepsis

Abbott claims new Bcl-XL/Bcl-2 inhibitors and their use in cancer therapy

New nitrooxy-containing probucol analogues recently patented by NicOx

Novel NPY antagonists prepared and tested at Banyu

GSK presents new inhibitors of Msk-1 and/or Rho kinases

New adamantane-based P2X7 antagonists under study at AstraZeneca

Antitumor fredericamycin analogues developed at Biofrontera

AstraZeneca scientists identify novel chemokine CCR5 modulators

New antihistaminic agents in early development at Sun Pharmaceutical

Synagis approved for expanded use in Europe

Risperdal Consta receives FDA approval

Seroquel deemed approvable by the FDA

Actimid enters phase II trial for prostate cancer

Chiron to initiate phase III tifacogin study in severe community-acquired pneumonia

Celltech gains European rights to Xyrem

Pfizer submits sNDA for Geodon for acute bipolar mania

TC-1734 successfully completes two phase I studies

Potent antiinflammatory effects described for new p38 kinase inhibitor

New triazoles from Meiji Seika exert in vitro and in vivo antifungal activity

FLG retains high efficacy against mutant HBV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...